Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. fertissimo

Fertissimo SIGNED

A ground-breaking medical system selecting the most viable embryo for successful IVF pregnancy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Fertissimo project word cloud

Explore the words cloud of the Fertissimo project. It provides you a very rough idea of what is the project "Fertissimo" about.

trial    pregnancies    facilities    fertissimo    pregnancy    ivi    qualified    centres    global    profile    procedure    ivf    forming    riskier    embryo    clinical    outcomes    rapid    utilises    os    culture    manner    equates    rates    conduct    reproductive    hospitals    conclusive    series    prospective    excellence    accommodate    solid    chances    oxidative    carmel    infrastructure    qualify    joins    standard    soon    risk    multiple    ultimate    embryos    industrially    rate    benefit    mothers    diagnostics    biomarker    physician    certify    engineering    accurate    transfer    medical    low    quantitative    morphology    dependable    media    create    lay    costly    validation    retrospective    incubated    basis    minimise    valencia    practiced    company    leader    efficient    clinics    invasive    unprecedented    located    legacy    aran    met    tools    predict    single    finances    stress    gold    line    forces    foundation    qualities    viability    unable    mass    25    innovation    2009   

Project "Fertissimo" data sheet

The following table provides information about the project.

Coordinator		 CARMEL DIAGNOSTICS LTD 

Organization address
address: 9 BARLEV HAIM STREET
city: QIRYAT TIVON
postcode: 3608267
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Project website http://www.fertissimoivf.com
 Total cost 2˙751˙973 €
 EC max contribution 2˙711˙973 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARMEL DIAGNOSTICS LTD IL (QIRYAT TIVON) coordinator 1˙446˙486.00
2    ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD IL (CAESAEA) participant 1˙265˙487.00

Map

 Project objective

Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.

Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.

The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability

Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production.

The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers

 Deliverables

List of deliverables.
Original Investor Relations Kit Dossier Websites, patent fillings, videos etc. 2019-03-20 11:46:21
Project website Websites, patent fillings, videos etc. 2019-03-20 11:46:21

Take a look to the deliverables list in detail:  detailed list of Fertissimo deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More